Iidiopathic thrombocytopenic purpura and autoimmune thyroid disease.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to A Aronstam.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A double-blind controlled trial of prophylactic factor VIII therapy has been carried out on nine severe haemophiliacs at the Lord Mayor Treloar College. Infusions were given once weekly and calculated to give a post-infusion plasma concentration of at least 0.25 I.U./ml of factor VIII. This regime reduced the overall bleeding frequency by 15%. The bleeding frequency in the first 3 days post-infusion was reduced by 66%. A moderate overall reduction in morbidity was also achieved. It is calculated that to reduce the incidence of bleeding in severe haemophiliacs by 15% would require a 73% increased usage of therapeutic materials. More than twice this amount of material is likely to be needed to reduce the bleeding frequency of the same group by 66%.
Explore the source record for details and available documents.
Initial half disappearance times and biological half-lives were determined for factor VIII procoagulant antigen (VIII:C Ag) and compared with VIII procoagulant (VIII:C) survival for each of two commercial concentrates, transfused into seven severe (less than 1 i.u./dl) non-bleeding haemophiliacs. The results show that VIII:C Ag has similar half disappearance and biological half-life to that of factor VIII:C. The relevance of these results to recently published findings is discussed.
Explore the source record for details and available documents.